crimeancongo
haemorrhag
fever
cchf
widespread
tickborn
viral
zoonosi
casefat
rate
rang
human
although
licens
vaccin
prevent
infect
cchf
viru
cchfv
exist
abil
induc
neutral
antibodi
limit
efficaci
cchfv
remain
undetermin
addit
control
cchf
infect
erad
tick
reservoir
ineffect
econom
logist
treatment
option
cchf
remain
limit
review
first
critic
discuss
exist
anim
model
evalu
therapeut
cchf
review
therapeut
option
cchf
investig
human
case
follow
investig
drug
evalu
preclin
studi
highlight
import
understand
human
prognost
factor
develop
anim
model
cchf
recapitul
hallmark
human
diseas
implic
select
therapeut
candid
anim
model
crimeancongo
haemorrhag
fever
prognost
marker
therapeut
crimeancongo
haemorrhag
fever
cchf
tickborn
diseas
caus
cchf
viru
cchfv
cchfv
character
crimean
outbreak
later
agent
caus
diseas
congo
casal
member
orthonairoviru
genu
within
nairovirida
famili
cchfv
primarili
transmit
direct
contact
skin
mucou
membran
infecti
blood
tissu
bite
infect
hyalomma
speci
tick
contact
virem
livestock
vorou
pierroutsako
maltez
furthermor
fatal
nosocomi
spread
cchfv
hospit
set
common
oestereich
et
al
upon
infect
cchf
progress
four
stage
diseas
incub
prehaemorrhag
haemorrhag
convalesc
durat
incub
stage
usual
day
cchfv
transmit
via
tick
bite
day
transmit
via
contact
infect
blood
tissu
prehaemorrhag
stage
follow
nonspecif
viral
symptom
fever
muscl
sore
chill
photophobia
headach
nausea
nonsever
case
individu
clear
infect
prehaemorrhag
stage
associ
symptom
resolv
sever
case
diseas
progress
haemorrhag
stage
occur
day
infect
symptom
petechia
haemorrhag
intern
organ
gastrointestin
system
gum
nose
shayan
bokaean
shahrivar
chinikar
fatal
case
usual
result
multipl
organ
failur
fatal
rate
cchf
rang
past
outbreak
dilber
et
al
surviv
haemorrhag
stage
experi
convalesc
phase
character
memori
loss
headach
dizzi
weak
puls
hair
loss
anorexia
vision
abnorm
shayan
et
al
longterm
sequela
neurolog
problem
impair
vision
document
howev
rare
perman
hoogstraal
date
still
unclear
whether
survivor
develop
immun
subsequ
cchfv
infect
igg
respons
lack
fatal
case
induc
nonfat
case
human
ergonul
tuncbilek
baykam
celikba
dokuzoguz
crimeancongo
haemorrhag
fever
geograph
widespread
zoonot
diseas
rang
middl
east
asia
south
africa
eastern
europ
howev
document
cchf
case
report
turkey
cchfv
remain
risk
pathogen
abil
caus
sever
fatal
diseas
human
absenc
effect
option
preor
postexposur
prophylaxi
circumst
cchfv
still
deem
possibl
weapon
bioterror
bronz
huyck
machado
voskuhl
greenfield
review
explor
past
summar
histor
measur
cchfv
control
prevent
review
present
state
exist
anim
model
evalu
therapeut
intervent
test
human
case
cchfv
infect
final
discuss
investig
drug
preclin
studi
review
aim
highlight
import
develop
anim
model
cchf
recapitul
hallmark
human
diseas
order
optim
preclin
drug
test
therebi
improv
chanc
develop
effect
medic
countermeasur
human
multipl
instanc
attempt
control
cchf
erad
cchfv
tick
vector
ineffici
econom
logist
keshtkarjahromi
et
al
remain
difficult
control
cchfv
cull
domest
anim
host
reservoir
cattl
goat
sheep
often
remain
asymptomat
even
highli
virem
whitehous
mani
nosocomi
outbreak
cchfv
occur
endem
area
burney
ghafoor
saleen
webb
casal
conger
et
al
naderi
sheybani
bojdi
khosravi
mostafavi
pshenichnaya
nenadskaya
isol
room
cchf
establish
treatment
unit
throughout
turkey
iran
pakistan
russia
georgia
bulgaria
india
kazakhstan
kosovo
addit
adequ
train
use
person
protect
equip
effect
wast
manag
disinfect
hospit
set
implement
fletcher
et
al
howev
cchf
case
often
enter
healthcar
facil
nonspecif
flulik
symptom
late
recognit
diagnosi
cchf
case
may
hinder
effect
measur
reduc
occurr
hospitalacquir
cchfv
infect
fletcher
et
al
anoth
attempt
control
cchfv
develop
inactiv
cchfv
vaccin
isol
brain
infect
rat
mice
vaccin
gain
approv
soviet
ministri
health
prevent
measur
cchf
demonstr
safeti
immunogen
human
although
vaccin
elicit
robust
tcell
respons
cchfv
high
antibodi
level
upon
initi
vaccin
four
dose
requir
induc
even
low
level
cchfvneutral
antibodi
mousavijazi
karlberg
papa
christova
mirazimi
date
protect
efficaci
vaccin
human
establish
control
clinic
trial
crude
natur
vaccin
prepar
make
less
like
candid
widespread
use
buttigieg
et
al
addit
correl
protect
cchfv
remain
unclear
develop
efficaci
vaccin
prevent
diseas
remain
obstacl
field
thu
absenc
adequ
prevent
option
therapeut
intervent
primari
mode
prevent
mortal
cchf
although
efficaci
remain
elus
evalu
therapeut
candid
cchf
hinder
due
histor
lack
anim
model
recapitul
hallmark
cchf
human
mani
anim
model
evalu
thu
far
develop
viremia
upon
infect
develop
clinic
featur
diseas
tabl
human
mammal
develop
diseas
upon
cchfv
infect
lack
fulli
function
immun
system
includ
neonat
mice
smirnova
signal
transduc
activ
transcript
knockout
mice
bent
et
al
interferon
receptor
knockout
mice
oestereich
et
al
thu
current
extens
use
anim
model
preclin
evalu
intervent
cchfv
crimeancongo
haemorrhag
fever
cchf
public
health
concern
rang
middl
east
asia
smirnova
nonleth
smirnova
increas
viremia
anticchfv
antibodi
smirnova
disadvantag
nonleth
clinic
sign
diseas
newborn
anim
white
rat
cotton
rat
variou
cchfv
isol
dose
ic
ip
vari
time
death
smirnova
increas
viremia
smirnova
advantag
lethal
model
costeffect
disadvantag
immatur
immun
system
prevent
evalu
vaccin
neonat
mice
pfu
cchfv
ibar
ic
ip
logan
et
al
day
postinfect
ip
logan
et
al
increas
viremia
lesion
logan
et
al
advantag
earliest
experiment
system
abl
induc
lethal
util
either
newborn
mice
rat
young
mice
infect
intracrani
intraperiton
salehi
salehi
adibi
salehi
newborn
mice
found
sensit
group
commonli
use
anim
model
studi
cchf
diseas
recent
newborn
mous
model
cchfv
use
studi
diseas
pathogenesi
efficaci
treatment
transmiss
dynam
viru
via
tick
logan
linthicum
bailey
watt
moulton
smirnova
zubri
savinov
chumakov
tignor
hanham
earli
use
newborn
mice
studi
cchfv
necessari
due
lack
diseas
seen
infect
adult
anim
sever
speci
viremia
could
detect
show
appar
sign
diseas
clear
viru
smirnova
howev
wide
use
earli
newborn
anim
model
typic
repres
diseas
progress
adult
anim
human
newborn
often
suscept
wide
rang
pathogen
caus
overt
diseas
matur
anim
interestingli
sever
larger
anim
experiment
infect
cchfv
sheep
cattl
donkey
ostrich
studi
persist
viru
speci
rather
model
human
diseas
smirnova
swanepoel
et
al
sinc
advent
genet
engin
techniqu
use
knockout
mice
proven
suitabl
model
studi
cchfv
pathogenesi
preclin
test
cchfv
vaccin
therapeut
knockout
mice
recent
use
lethal
model
cchf
diseas
bent
et
al
bereczki
et
al
zivcec
et
al
anim
model
defect
innat
immun
respons
believ
critic
protect
mice
product
infect
cchfv
defici
prevent
upregul
gene
due
signal
either
type
type
ii
interferon
knockout
mice
succumb
infect
within
day
suffer
fever
leukopenia
thrombocytopenia
elev
liver
enzym
bent
et
al
knockout
mice
also
high
level
viremia
liver
spleen
along
elev
proinflammatori
cytokin
product
contrast
genet
defect
mice
specif
affect
interferon
type
signal
mice
infect
cchfv
develop
acut
diseas
succumb
infect
within
day
bereczki
et
al
zivcec
et
al
high
viral
load
seen
spleen
liver
kidney
heart
lung
lymph
node
blood
mice
bereczki
et
al
zivcec
et
al
addit
signific
enlarg
liver
infect
mice
advantag
use
mous
model
advantag
bereczki
et
al
swanepoel
et
al
zivcec
et
al
model
use
studi
pathogenesi
diseas
well
test
treatment
option
also
provid
insight
immunolog
mechan
diseas
viral
clearanc
although
use
immunocompromis
mice
test
vaccin
ideal
model
also
suitabl
model
test
vaccin
provid
option
avail
use
newborn
anim
interest
advanc
anim
model
could
potenti
serv
model
cchf
diseas
human
mice
contrast
previou
mous
model
cchfv
infect
mice
develop
function
human
immun
system
includ
product
b
cell
follow
engraft
hematopoiet
stem
cell
pbmc
foetal
liver
thymu
brehm
shultz
greiner
treatment
demonstr
therapeut
benefit
human
statist
signific
establish
thu
far
support
smallmolecul
drug
implic
treatment
infect
caus
varieti
dna
rna
viru
infect
respiratori
syncyti
viru
hepat
c
viru
dusheiko
et
al
hall
et
al
also
demonstr
efficaci
treatment
haemorrhag
fever
caus
lassa
viru
infect
mccormick
et
al
synthes
ribavirin
purin
nucleosid
analogu
directli
inhibit
viral
transcript
bind
viral
polymeras
incorpor
nascent
rna
genom
caus
viral
rna
mutagenesi
also
directli
inhibit
translat
inhibit
viral
cap
enzym
tam
lau
hong
ribavirin
also
indirectli
mediat
antivir
activ
via
immunomodulatori
effect
induc
antivir
type
cytokin
suppress
provir
cytokin
tam
et
al
lastli
inhibit
host
inosin
monophosph
dehydrogenas
disrupt
intracellular
gtp
concentr
need
viral
replic
tam
et
al
cchfv
sensit
ribavirin
straindepend
manner
vitro
watt
usseri
nash
peter
cchfv
strain
ibar
nigeria
spu
south
africa
china
highli
sensit
ribavirin
effect
inhibitori
dose
cchfv
strain
ug
uganda
greec
spu
south
africa
less
sensit
ribavirin
control
prevent
promot
use
ribavirin
treatment
cchf
efficaci
ribavirin
human
cchf
case
remain
controversi
favour
ribavirin
cchf
therapeut
efficaci
oral
ribavirin
suspect
confirm
cchf
patient
studi
conduct
iran
respect
mardani
jahromi
naieni
zeinali
eight
cchf
patient
surviv
sever
diseas
administ
oral
ribavirin
within
mean
day
et
al
multivari
analysi
confirm
cchf
patient
turkish
hospit
demonstr
treat
oral
ribavirin
admit
within
day
symptom
onset
decreas
risk
experienc
sever
diseas
ozbey
kader
erbay
similar
multivari
analysi
cchf
patient
stratifi
diseas
sever
anoth
site
turkey
ribavirin
found
effect
reduc
casefat
rate
among
moder
ill
patient
dokuzoguz
et
al
contrast
current
studi
support
conclus
ribavirin
effect
treatment
cchf
metaanalysi
conduct
one
random
control
trial
seven
observ
studi
demonstr
ribavirin
improv
surviv
cchf
patient
unabl
provid
signific
clinic
benefit
ascioglu
leblebicioglu
vahaboglu
chan
studi
oral
ribavirin
treatment
cchf
patient
confer
signific
benefit
regard
viral
load
diseas
progress
compar
patient
receiv
ribavirin
improv
surviv
rate
bodur
et
al
ceylan
ak
akkoyunlu
turhan
elaldi
et
al
addit
patient
given
ribavirin
experienc
delay
return
normal
leucocyt
count
longer
hospit
time
howev
find
statist
signific
discrep
surround
efficaci
methylprednisolon
synthet
corticosteroid
licens
treatment
inflammatori
ailment
arthriti
bronchiti
well
autoimmun
diseas
system
lupu
erythematosu
multipl
sclerosi
sloka
stefanelli
methylprednisolon
bind
intracellular
glucocorticoid
receptor
activ
express
gene
modul
immun
system
aid
restor
blood
barrier
disrupt
antiinflammatori
effect
methylprednisolon
believ
benefit
case
diseas
pathogenesi
mediat
deleteri
host
immun
respons
tam
et
al
methylprednisolon
evalu
human
trial
viral
ailment
coronavirusassoci
sever
acut
respiratori
syndrom
sar
dengu
viru
howev
studi
fail
establish
statist
signific
efficaci
corticosteroid
treatment
patient
auyeung
et
al
ho
et
al
tam
et
al
convalesc
blood
product
harvest
recov
patient
aim
provid
pathogenspecif
antibodi
gener
diseas
progress
newli
infect
patient
success
treatment
diseas
measl
whoop
cough
typhoid
fever
scarlet
fever
mump
berger
dewar
mcguin
stoke
mudd
stoll
although
ef
day
follow
symptom
onset
exhibit
statist
improv
outcom
nontreat
patient
leshchinskaya
martinenko
patient
administ
ml
convalesc
serum
nosocomi
outbreak
cchf
dubai
surviv
ill
experienc
shorter
convalesc
period
compar
survivor
suleiman
et
al
furthermor
find
would
suggest
administr
protect
antibodi
may
success
direct
explor
prognost
factor
predict
mortal
cchfv
case
continu
crucial
import
field
medic
set
abil
predict
clinic
cours
diseas
allow
physician
make
crucial
decis
diseas
manag
whether
patient
could
manag
local
hospit
transport
medic
centr
greater
intens
care
capac
identifi
factor
strongli
associ
fatal
may
allow
optim
anim
model
ideal
exhibit
similar
clinic
sign
laboratori
find
human
select
therapeut
agent
specif
address
sign
biomark
may
show
benefit
prevent
mortal
human
case
mani
studi
attempt
understand
clinic
sign
associ
mortal
human
compar
seen
fatal
nonfat
cchf
case
ergonul
celikba
baykam
eren
dokuzoguz
ozturk
et
al
earli
diseas
cours
cchf
patient
present
fever
loss
appetit
howev
significantli
associ
mortal
bleed
key
featur
subsequ
haemorrhag
stage
cchfv
infect
cevik
et
al
depict
tabl
hematemesi
blood
vomit
epistaxi
bloodi
nose
gingiv
bleed
melena
blood
stool
shown
multipl
studi
significantli
associ
death
cevik
et
al
ergonul
tuncbilek
et
al
kaya
et
al
ozturk
et
al
bleed
skin
signific
prognost
factor
studi
ozturk
et
al
addit
overal
consensu
studi
show
somnol
anoth
clinic
sign
significantli
associ
mortal
petechia
maculopapular
rash
hepatomegali
splenomegali
eccymosi
jaundic
often
seen
cchf
patient
current
signific
sign
mortal
date
neonat
mice
mice
knockout
mice
mice
unabl
demonstr
clinic
sign
upon
cchfv
infect
howev
mice
knockout
mice
mice
demonstr
loss
appetit
show
cchfv
antigen
liver
spleen
bent
et
al
spengler
et
al
zivcec
et
al
abnorm
blood
clot
result
thrombocytopenia
establish
mortal
factor
cchf
case
studi
compar
coagulopathi
marker
fatal
cchf
case
n
nonfat
patient
n
signific
prognost
factor
associ
mortal
identifi
mani
studi
demonstr
abnorm
leucocyt
count
elev
liver
enzym
hallmark
cchfv
infect
use
predict
fatal
outcom
patient
retrospect
studi
compris
cchfv
patient
confirm
pcr
anticchfv
igm
antibodi
leucocyt
lymphocyt
neutrophil
monocyt
level
compar
fatal
n
nonfat
n
case
use
receiv
oper
curv
analysi
signific
risk
factor
mortal
establish
studi
increas
neutrophil
level
p
decreas
lymphocyt
p
monocyt
p
level
independ
predictor
mortal
leucocyt
per
lactat
dehydrogenas
ul
alanin
aminotransferas
ul
increas
mortal
risk
bastug
et
al
studi
suggest
import
cchfv
ozturk
et
al
still
unknown
whether
viru
neutral
antibodymedi
mechan
correl
protect
knockout
mous
model
demonstr
leukopenia
infect
cchfv
bent
et
al
zivcec
et
al
factor
yet
examin
mous
model
spengler
et
al
anoth
comparison
fatal
n
nonfat
n
case
cchfv
increas
vs
pgml
p
vs
pgml
p
identifi
signific
marker
mortal
level
decreas
fatal
case
compar
survivor
statist
signific
level
similar
group
kaya
et
al
recent
student
studi
similarli
show
increas
fatal
case
n
compar
nonfat
case
n
addit
marker
fatal
et
al
mention
previous
cchf
therapeut
howev
ribavirin
methylprednisolon
clinic
approv
drug
undergon
phase
safeti
test
human
absenc
therapeut
proven
benefit
cchfv
ribavirin
repurpos
evalu
phase
ii
iii
efficaci
trial
howev
lack
signific
benefit
confer
ribavirin
cchf
patient
trial
may
predict
outcom
ta
b
l
e
therapeut
option
treatment
crimeancongo
haemorrhag
fever
ribavirin
inhibit
viral
replic
indirectli
modul
host
immun
respons
tam
et
al
inhibit
cchfv
replic
vero
cell
line
oestereich
et
al
mice
ffu
cchfv
protect
administ
dpi
oestereich
et
al
knockout
mice
pfu
cchfv
protect
daili
regimen
initi
hr
postinfect
dpi
bent
et
al
knockout
mice
pfu
cchfv
protect
given
hr
postinfect
dpi
bent
et
al
proribavirin
improv
surviv
diseas
sever
dokuzoguz
et
al
mardani
et
al
ozbey
et
al
antiribavirin
statist
signific
improv
outcom
cchf
patient
treat
ribavirin
ascioglu
et
al
bodur
et
al
ceylan
et
al
elaldi
et
al
koksal
et
al
methylprednisolon
modul
host
immun
respons
tam
et
al
avail
anim
data
avail
cchf
patient
surviv
administ
dose
mg
per
kgday
intraven
day
administr
ivig
andor
gcsf
dilber
et
al
convalesc
blood
product
antibodymedi
effect
neutral
antibodydepend
cell
cytotox
anim
data
avail
patient
treat
convalesc
serum
surviv
diseas
suleiman
et
al
patient
treat
hyperimmun
serum
surviv
diseas
monoclon
antibodi
antibodymedi
effect
neutral
antibodydepend
cell
cytotox
antigc
mab
neutral
cchfv
infect
cell
antign
mab
demonstr
less
neutral
activ
cchfv
cell
bertolotticiarlet
et
al
neonat
mice
antigc
protect
administ
day
infect
administ
dpi
antigc
protect
administ
day
infect
antign
protect
administ
day
infect
protect
administ
dpi
antign
protect
administ
day
infect
protect
administ
dpi
bertolotticiarlet
et
al
test
human
cchf
case
favipiravir
inhibit
viral
rna
polymeras
janeba
li
chan
lee
salata
et
al
inhibit
cchfv
replic
vero
cell
line
oestereich
et
al
mice
ffu
cchfv
protect
treatment
initi
dpi
oestereich
et
al
test
human
cchf
case
continu
demonstr
lack
effect
patient
dun
et
al
guptawright
laver
irvin
observ
suggest
lack
prior
efficaci
test
current
anim
model
infect
may
contribut
drug
lack
benefit
clinic
trial
mendoza
qiu
kobing
thu
futur
cchfv
drug
candid
commonli
undergo
preclin
test
avail
anim
model
cchfv
may
allow
better
predict
effect
test
human
patient
tabl
although
ribavirin
evalu
human
case
cchfv
evalu
anim
model
cchf
recent
studi
use
mous
model
cchf
ribavirin
demonstr
statist
signific
efficaci
strain
cchfv
infect
mice
administ
dpi
oestereich
et
al
contrast
ribavirin
abl
protect
knockout
mice
pfu
cchfv
challeng
daili
treatment
initi
hr
postinfect
hr
postinfect
bent
et
al
howev
challeng
pfu
cchfv
anim
surviv
treatment
initi
hr
postinfect
anim
surviv
treatment
initi
hr
postinfect
bent
et
al
monoclon
antibodi
mab
target
gn
andor
gc
surfac
glycoprotein
cchfv
origin
develop
identifi
cchfv
current
investig
treatment
cchf
blackburn
besselaar
shepherd
swanepoel
vitro
gcspecif
gnspecif
mab
abl
neutral
cchfv
infect
cell
bertolotticiarlet
et
al
protect
achiev
suckl
mice
administ
antigc
mab
hr
prior
lethal
cchfv
challeng
howev
protect
achiev
administ
hr
postcchfv
infect
contrast
protect
achiev
antign
mab
administ
hr
postinfect
suggest
mechan
antibodydepend
cell
cytotox
complementmedi
cell
lysi
may
play
role
protect
cchfv
bertolotticiarlet
et
al
would
interest
assess
efficaci
antibodybas
therapeut
model
better
recapitul
human
diseas
stat
ko
mice
arbidol
broadspectrum
antivir
interrupt
clathrindepend
traffick
therebi
inhibit
viral
entri
blais
et
al
arbidol
use
treat
influenza
viru
human
elicit
inhibit
viru
entri
replic
virus
hepat
c
viru
vitro
et
al
favipiravir
broadspectrum
select
inhibitor
viral
rna
polymeras
demonstr
efficaci
influenza
viru
infect
human
furuta
et
al
studi
oestereich
et
al
arbidol
arbidol
inhibit
viral
entri
blais
et
al
inhibit
cchfv
replic
vero
cell
line
oestereich
et
al
mice
ffu
cchfv
protect
administ
day
infect
oestereich
et
al
mice
ffu
cchfv
protect
administ
day
infect
oestereich
et
al
test
human
cchf
case
chloroquin
inhibit
uncoat
posttransl
modif
modul
host
immun
respons
savarino
et
al
inhibit
cchfv
replic
vero
cell
line
ferrari
et
al
anim
data
avail
test
human
cchf
case
chlorpromazin
inhibit
format
clathrinco
pit
prevent
clathrinmedi
endocytosi
viral
uncoat
wang
et
al
inhibit
cchfv
vero
cell
line
ferrari
et
al
anim
data
avail
test
human
cchf
case
ta
b
l
e
continu
chloroquin
broadspectrum
antivir
inhibit
phdepend
step
viral
replic
includ
uncoat
posttransl
modif
like
increas
ph
endosom
lysosom
golgi
vesicl
addit
chloroquin
elicit
immunomodulatori
effect
inhibit
product
andor
releas
tumour
necrosi
factor
savarino
boelaert
casson
majori
cauda
chloroquin
use
treat
malaria
shown
inhibit
replic
influenza
viru
chikungunya
viru
dengu
viru
cell
cultur
faria
machado
de
almeida
junior
de
aquino
da
fonseca
khan
santhosh
tiwari
lakshmana
rao
parida
ooi
chew
loh
chua
chlorpromazin
licens
antipsychot
drug
use
treatment
bipolar
disord
schizophrenia
gajwani
et
al
leucht
kitzmantel
chua
kane
leucht
chlorpromazin
also
demonstr
antivir
activ
adenoviru
infect
syrian
hamster
diaconu
et
al
also
inhibit
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
cell
cultur
bhattacharyya
et
al
de
wild
et
al
antivir
activ
chlorpromazin
like
mediat
interfer
clathrinco
pit
prevent
clathrinmedi
endocytosi
viral
uncoat
wang
rothberg
anderson
chloroquin
chlorpromazin
abl
inhibit
cchfv
infect
vero
cell
line
ad
hr
postinfect
hr
ferrari
et
al
next
step
would
involv
evalu
drug
anim
model
cchfv
infect
develop
lethal
anim
model
cchfv
infect
allow
evalu
newli
develop
vaccin
candid
protect
cchfv
vaccin
platform
demonstr
protect
efficaci
small
anim
model
understand
correl
protect
cchfv
infect
human
remain
incomplet
buttigieg
et
al
dowal
carrol
hewson
character
specif
immun
respons
optim
protect
cchfv
infect
human
crucial
futur
vaccin
develop
drosophila
insect
cellbas
express
system
use
develop
subunit
vaccin
compris
ectodomain
structur
cchfv
glycoprotein
gn
gc
kortekaa
et
al
vaccin
induc
cchfvneutral
antibodi
knockout
mice
administ
primeboost
regimen
howev
vaccin
unabl
offer
protect
knockout
mous
model
cchfv
infect
lethal
challeng
intraperiton
strain
day
postvaccin
kortekaa
et
al
result
studi
suggest
cchfvneutral
antibodi
may
correl
protect
futur
studi
evalu
role
viru
neutral
anim
model
cchfv
infect
determin
whether
modelspecif
phenomenon
featur
mimic
human
respons
infect
strain
day
postprim
vaccin
buttigieg
et
al
studi
show
protect
confer
mvagp
vaccin
mice
requir
cellular
humor
respons
dowal
et
al
futur
research
evalu
either
respons
requir
protect
cchfv
human
case
garrison
et
al
studi
found
direct
correl
anticchfv
glycoprotein
antibodi
respons
surviv
suggest
antibodi
target
cchfv
protein
andor
cellular
respons
may
involv
vaccinemedi
protect
garrison
et
al
dna
vaccin
advantag
costeffect
abil
induc
robust
cytotox
tcell
respons
enhanc
stabil
differ
temperatur
limit
term
immunogen
requir
adjuv
electropor
induc
adequ
antibodi
respons
clem
khan
potenti
widespread
geograph
distribut
highli
lethal
outbreak
diseas
make
cchf
import
emerg
infecti
diseas
renew
interest
develop
vaccin
therapeut
approach
exist
biocontain
requir
lack
suitabl
anim
model
limit
research
advanc
area
due
zoonot
natur
diseas
lack
approv
therapi
rais
awar
among
risk
critic
prevent
cchf
sever
therapeut
approach
examin
efficaci
variabl
remain
need
reliabl
therapeut
develop
test
reliabl
therapeut
option
reli
upon
advanc
understand
diseas
pathogenesi
anim
model
date
lack
suitabl
anim
model
would
open
door
potenti
vaccin
therapeut
research
achiev
far
neonat
immunodefici
anim
limit
assess
cours
diseas
test
potenti
vaccin
platform
optim
advanc
anim
model
human
mice
advanc
understand
diseas
progress
immunolog
correl
protect
cchf
approach
might
best
prevent
diseas
evalu
pathogenesi
human
virus
anim
ideal
model
abl
host
viru
replic
exhibit
similar
prognost
marker
seen
human
case
recapitul
hallmark
human
diseas
advanc
transgen
knockout
anim
model
characterist
would
optim
preclin
develop
therapeut
candid
yield
benefit
human
cchf
patient
immun
correl
protect
also
provid
valuabl
inform
develop
specif
therapi
antibodi
develop
antiinflammatori
mediat
steroid
current
understand
cchf
establish
use
limit
anim
model
clinic
data
futur
direct
aim
develop
ideal
model
infect
preclin
test
vaccin
therapeut
cchf
futur
advanc
area
would
pave
way
inform
research
work
toward
effect
vaccin
medic
countermeasur
cchf
author
declar
conflict
interest
author
relev
affili
financi
involv
organ
entiti
financi
interest
subject
matter
manuscript
rci
c
ranadheera
http
